Ahmedabad, Gujarat, India – Business Wire India
Zydus Lifesciences Limited, a global leader in innovation within the life sciences sector, has launched Semaglutide Injection in India, marketed under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM. This introduction comes after the expiry of the relevant patent, following the approval from the Drug Controller General of India (DCGI) for both the manufacturing and marketing of this injection, aimed at treating Type 2 Diabetes Mellitus and obesity.
The innovative feature of this product is its reusable multi-dose pen device, which is designed to enhance patient experience. Unlike existing treatment options that necessitate the purchase of multiple single-dose pens for dosage titration, Zydus’ novel pen allows for the selection and administration of varying dose strengths from a single cartridge. This advancement is anticipated to improve patient adherence, increase convenience, and significantly reduce the overall cost of therapy.
The Semaglutide injection will be available in a 15mg/3ml cartridge, produced at Zydus Biotech Park in Ahmedabad. The estimated average monthly cost for patients will be around Rs. 2,200.
Diabetes and obesity are critical health challenges facing India today. As reported by the International Diabetes Federation, approximately 8.9 crore adults in India are living with diabetes, constituting 10.5 per cent of the adult population. Concurrently, the prevalence of obesity has escalated across various age groups, with a 91 per cent increase in obesity among women and a staggering 146 per cent rise among men over recent years.
This data highlights a significant public health crisis, underscoring the necessity for effective treatments. GLP-1 based therapies, such as Semaglutide, are positioned to play a pivotal role in addressing these escalating health concerns.
About Zydus Lifesciences Limited: Zydus Lifesciences Ltd. is committed to empowering individuals to lead healthier and more fulfilling lives. The company is deeply invested in the discovery, development, manufacturing, and marketing of a wide range of healthcare therapies. With a workforce of over 29,000 people globally, including 1,500 scientists dedicated to research and development, Zydus is driven by its mission to unlock new possibilities in life sciences through high-quality healthcare solutions. The organisation aims to transform lives through groundbreaking discoveries and has introduced numerous first-in-class products over the last decade, addressing unmet healthcare needs with a focus on vaccines, therapeutics, biologicals, and new chemical entities.
For more information, visit www.zyduslife.com.
References:
1. Data on file, Permission to Manufacture Pharmaceutical Formulation of New Drug for Sale or for Distribution, CDSCO
2. Prevalence of Obesity in India, UNICEF India